GlaxoSmithKline | GSK - Interest Expense On Debt


GlaxoSmithKline reported GBP167M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alcon AG USD 52M 2M Mar/2026
Amgen USD 657M 4M Mar/2026
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 79M 6M Mar/2026
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 104M 17M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Orion EUR 1.4M 800K Mar/2026
Pfizer USD 671M 40M Mar/2026
Philips EUR 83M 26M Mar/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Smith & Nephew USD 69M 1000K Dec/2025
UCB EUR 49M 29M Dec/2025